Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

4T1 Mammary Carcinoma Colonization of Metastatic Niches Is Accelerated by Obesity.

Evangelista GCM, Salvador PA, Soares SMA, Barros LRC, Xavier FHDC, Abdo LM, Gualberto ACM, Macedo GC, Clavijo-Salomon MA, Gameiro J.

Front Oncol. 2019 Sep 20;9:685. doi: 10.3389/fonc.2019.00685. eCollection 2019.

2.

Topical application of the hexane fraction of Lacistema pubescens reduces skin inflammation and cytokine production in animal model.

da Silva JM, Conegundes JL, Mendes Rde F, Pinto Nde C, Gualberto AC, Ribeiro A, Gameiro J, de Aguiar JA, Castañon MC, Scio E.

J Pharm Pharmacol. 2015 Nov;67(11):1613-22. doi: 10.1111/jphp.12463. Epub 2015 Aug 5.

PMID:
26245821
3.

Plasmodium berghei ANKA infection results in exacerbated immune responses from C57BL/6 mice displaying hypothalamic obesity.

de Carvalho RVH, Soares SMA, Gualberto ACM, Evangelista GCM, Duque JAM, Ferreira AP, Macedo GC, Gameiro J.

Cytokine. 2015 Dec;76(2):545-548. doi: 10.1016/j.cyto.2015.01.025. Epub 2015 Jul 31. No abstract available.

PMID:
26239414
4.

Pereskia aculeata Miller leaves present in vivo topical anti-inflammatory activity in models of acute and chronic dermatitis.

Pinto Nde C, Machado DC, da Silva JM, Conegundes JL, Gualberto AC, Gameiro J, Moreira Chedier L, Castañon MC, Scio E.

J Ethnopharmacol. 2015 Sep 15;173:330-7. doi: 10.1016/j.jep.2015.07.032. Epub 2015 Jul 28.

5.

Experimental infection of inbred BALB/c and A/J mice with Massachusetts and Brazilian strains of infectious bronchitis virus (IBV).

Martini MC, Gameiro J, Cardoso TC, Caserta LC, Gualberto AC, Keid LB, Oliveira TM, dos Santos MM, Arns CW, Ferreira HL.

Arch Virol. 2015 Jul;160(7):1785-90. doi: 10.1007/s00705-015-2443-x. Epub 2015 May 9.

PMID:
25951972
6.

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.

Gualberto A.

Expert Opin Investig Drugs. 2012 Feb;21(2):205-16. doi: 10.1517/13543784.2011.641532. Epub 2011 Nov 30. Review.

PMID:
22127011
7.

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.

Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A.

J Clin Oncol. 2011 Dec 1;29(34):4534-40. doi: 10.1200/JCO.2010.33.0670. Epub 2011 Oct 24.

8.

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.

Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN.

Br J Cancer. 2011 Jan 4;104(1):68-74. doi: 10.1038/sj.bjc.6605972. Epub 2010 Nov 23. Retraction in: Br J Cancer. 2012 Dec 4;107(12):2024.

9.

The evolving role of histology in the management of advanced non-small-cell lung cancer.

Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC.

J Clin Oncol. 2010 Dec 20;28(36):5311-20. doi: 10.1200/JCO.2010.28.8126. Epub 2010 Nov 15. Review.

PMID:
21079145
10.

Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.

Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV.

Clin Cancer Res. 2010 Sep 15;16(18):4654-65. doi: 10.1158/1078-0432.CCR-10-0089. Epub 2010 Jul 29. Retraction in: Clin Cancer Res. 2014 Jun 15;20(12):3358.

11.

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.

Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS.

Br J Cancer. 2010 Jul 27;103(3):332-9. doi: 10.1038/sj.bjc.6605767. Epub 2010 Jul 13.

12.

Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway.

Hixon ML, Paccagnella L, Millham R, Perez-Olle R, Gualberto A.

Rev Recent Clin Trials. 2010 Sep;5(3):189-208. Review.

PMID:
20533896
13.

Figitumumab (CP-751,871) for cancer therapy.

Gualberto A.

Expert Opin Biol Ther. 2010 Apr;10(4):575-85. doi: 10.1517/14712591003689980. Review. Erratum in: Expert Opin Biol Ther. 2014 May;14(5):741.

PMID:
20175655
14.

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P.

Lancet Oncol. 2010 Feb;11(2):129-35. doi: 10.1016/S1470-2045(09)70354-7. Epub 2009 Dec 23.

15.

Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.

Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A.

J Thorac Oncol. 2009 Nov;4(11):1397-403. doi: 10.1097/JTO.0b013e3181ba2f1d.

16.

Clinical development of inhibitors of the insulin-like growth factor receptor in oncology.

Gualberto A, Pollak M.

Curr Drug Targets. 2009 Oct;10(10):923-36. Review.

PMID:
19663769
17.

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.

Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, de Bono JS, Gualberto A, Hammer GD.

Cancer Chemother Pharmacol. 2010 Mar;65(4):765-73. doi: 10.1007/s00280-009-1083-9. Epub 2009 Aug 2.

18.
19.

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.

Gualberto A, Pollak M.

Oncogene. 2009 Aug 27;28(34):3009-21. doi: 10.1038/onc.2009.172. Epub 2009 Jul 6. Review.

PMID:
19581933
20.

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G Jr, Johnson FM, Green S, Gualberto A.

J Clin Oncol. 2009 May 20;27(15):2516-22. doi: 10.1200/JCO.2008.19.9331. Epub 2009 Apr 20. Retraction in: J Clin Oncol. 2012 Nov 20;30(33):4179.

PMID:
19380445
21.

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.

Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P, Gualberto A.

J Clin Oncol. 2008 Jul 1;26(19):3196-203. doi: 10.1200/JCO.2007.15.9319. Epub 2008 May 12.

PMID:
18474873
22.

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.

Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A.

J Transl Med. 2008 May 1;6:22. doi: 10.1186/1479-5876-6-22.

23.

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.

Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS.

Clin Cancer Res. 2007 Oct 1;13(19):5834-40.

24.

Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor.

de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A.

Clin Cancer Res. 2007 Jun 15;13(12):3611-6.

25.

Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays.

Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A.

Clin Cancer Res. 2006 Jan 1;12(1):107-16.

26.

IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma.

Chng WJ, Gualberto A, Fonseca R.

Leukemia. 2006 Jan;20(1):174-6. No abstract available.

PMID:
16239907
27.

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD.

Clin Cancer Res. 2005 Mar 1;11(5):2063-73.

28.

Loss of mitotic spindle checkpoint activity predisposes to chromosomal instability at early stages of fibrosarcoma development.

Gascoyne DM, Hixon ML, Gualberto A, Vivanco MD.

Cell Cycle. 2003 May-Jun;2(3):238-45.

PMID:
12734433
29.

Vascular smooth muscle polyploidization--from mitotic checkpoints to hypertension.

Hixon ML, Gualberto A.

Cell Cycle. 2003 Mar-Apr;2(2):105-10. Review.

PMID:
12695657
30.

Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes.

Wang Y, De Keulenaer GW, Weinberg EO, Muangman S, Gualberto A, Landschulz KT, Turi TG, Thompson JF, Lee RT.

Am J Physiol Heart Circ Physiol. 2002 Aug;283(2):H533-9.

31.

Macrophage inducible nitric oxide synthase gene expression is blocked by a benzothiophene derivative with anti-HIV properties.

Carballo M, Conde M, Tejedo J, Gualberto A, Jimenez J, Monteseirín J, Santa María C, Bedoya FJ, Hunt SW 3rd, Pintado E, Baldwin AS Jr, Sobrino F.

Mol Genet Metab. 2002 Apr;75(4):360-8.

PMID:
12051968
32.

Akt1/PKB upregulation leads to vascular smooth muscle cell hypertrophy and polyploidization.

Hixon ML, Muro-Cacho C, Wagner MW, Obejero-Paz C, Millie E, Fujio Y, Kureishi Y, Hassold T, Walsh K, Gualberto A.

J Clin Invest. 2000 Oct;106(8):1011-20.

33.

Cks1 mediates vascular smooth muscle cell polyploidization.

Hixon ML, Obejero-Paz C, Muro-Cacho C, Wagner MW, Millie E, Nagy J, Hassold TJ, Gualberto A.

J Biol Chem. 2000 Dec 22;275(51):40434-42.

34.

Gain of function properties of mutant p53 proteins at the mitotic spindle cell cycle checkpoint.

Hixon ML, Flores A, Wagner M, Gualberto A.

Histol Histopathol. 2000 Apr;15(2):551-6. doi: 10.14670/HH-15.551. Review.

PMID:
10809376
35.

Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training.

Eto Y, Yonekura K, Sonoda M, Arai N, Sata M, Sugiura S, Takenaka K, Gualberto A, Hixon ML, Wagner MW, Aoyagi T.

Circulation. 2000 May 9;101(18):2134-7.

PMID:
10801751
36.

The control of mitosis.

Hixon ML, Gualberto A.

Front Biosci. 2000 Jan 1;5:D50-7. Review.

PMID:
10702375
37.

DNA replication and smooth muscle cell hypertrophy.

Walsh K, Shiojima I, Gualberto A.

J Clin Invest. 1999 Sep;104(6):673-4. No abstract available.

38.

p53 is a transcriptional activator of the muscle-specific phosphoglycerate mutase gene and contributes in vivo to the control of its cardiac expression.

Ruiz-Lozano P, Hixon ML, Wagner MW, Flores AI, Ikawa S, Baldwin AS Jr, Chien KR, Gualberto A.

Cell Growth Differ. 1999 May;10(5):295-306.

39.
40.

Calcineurin inhibitors and cardiac hypertrophy.

Luo Z, Shyu KG, Gualberto A, Walsh K.

Nat Med. 1998 Oct;4(10):1092-3. No abstract available.

PMID:
9771723
41.

Prevention of cardiac hypertrophy in mice by calcineurin inhibition.

Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, Molkentin JD.

Science. 1998 Sep 11;281(5383):1690-3.

42.

An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.

Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD.

Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5166-71.

43.

p53 transactivation of the HIV-1 long terminal repeat is blocked by PD 144795, a calcineurin-inhibitor with anti-HIV properties.

Gualberto A, Marquez G, Carballo M, Youngblood GL, Hunt SW 3rd, Baldwin AS, Sobrino F.

J Biol Chem. 1998 Mar 20;273(12):7088-93.

44.
46.

Genomic instability and cancer.

Tlsty TD, Briot A, Gualberto A, Hall I, Hess S, Hixon M, Kuppuswamy D, Romanov S, Sage M, White A.

Mutat Res. 1995 Jul;337(1):1-7. Review. No abstract available.

PMID:
7596354
47.
48.

Parameters that influence the extent of site occupancy by a candidate telomere end-binding protein.

Gualberto A, Lowry J, Santoro IM, Walsh K.

J Biol Chem. 1995 Mar 3;270(9):4509-17.

49.

Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors.

Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr.

Mol Cell Biol. 1995 Feb;15(2):943-53.

50.

The gene encoding rat phosphoglycerate mutase subunit M: cloning and promoter analysis in skeletal muscle cells.

Ruiz-Lozano P, de Lecea L, Buesa C, Pérez de la Osa P, LePage D, Gualberto A, Walsh K, Pons G.

Gene. 1994 Sep 30;147(2):243-8.

PMID:
7926808

Supplemental Content

Loading ...
Support Center